mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range from embracing AI to a 'bold campaign' of cancer vaccine studies.
Moderna and Generation Bio plan to develop non-viral genetic medicines for immune system and liver disorders under an up-to-$1.9 billion collaboration.
Moderna and Life Edit partner to accelerate gene editing therapies pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Moderna is partnering with Life Edit, a subsidiary of ElevateBio that offers a suite of gene-editing technologies. The deal brings together the capabilities of both companies, which aim to develop in vivo gene-editing therapies.Mod